PHOENIX (Geographic Atrophy)

Purpose of this Study

We are doing this study to find out if an investigational drug called tinlarebant (the study drug) is safe and useful for treating geographic atrophy (GA).

Who Can Participate?

Eligibility

Adults ages 60-85 who:
  • Are diagnosed with geographic atrophy with lesions
  • Do not have diabetic macular edema or another form of macular disease
  • Have no inflammatory disease
For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.

Age Range

60-85

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join the study, you will:
  • Get a random assignment (like a coin flip) to take the study drug or a placebo (inactive substance)
  • Keep in touch with the study team for about 2 years and 2 months
  • Visit our clinic at the Duke Eye Center up to 11 times
At various visits, you will have blood tests, answer some questionnaires, and have eye exams and vision tests.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX study) - LBS-008-CT05

Principal Investigator

Eleonora
Lad

Protocol Number

PRO00113726

NCT ID

NCT05949593

Phase

III

Enrollment Status

Open to Enrollment
ClinicalTrials.gov